RecruitingCholesterol; Lipidosis
Liver Adiposity Effects on Pediatric Statin
Eligible age
8–21 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Single center, open-label, prospective investigation to quantify the effects hepatocellular fat has on hepatic statin transport and response in children and adolescents in obese and non-obese children and adolescents 8-21 years of age with normal, wild-type SLCO1B1 c.521TT genotype that are dosed rosuvastatin
Sponsor: Children's Mercy Hospital Kansas City
You may qualify if…
- ✓ 8-21 years
- ✓ LDL cholesterol \>130mg/dl (\>95% percentile)
- ✓ SLCO1B1 c.521TT genotype
- ✓ Provide informed permission-assent(\<18 yrs.) or consent (≥18 yrs.)
- ✓ Fasting overnight (\~8 hrs.)
- ✓ Enrolled in Cardiology Pharmacogenomic Repository
You may not qualify if…
- ✕ Pregnancy
- ✕ Non-fasting
- ✕ Non-removable metal in body or MRI unsafe
- ✕ Currently on statin therapy and unwilling to wash out of statin therapy for at least 4 weeks prior to Visit 1 and throughout the duration of the study.
- ✕ Underlying unrepaired congenital or acquired cardiovascular defects or repaired congenital or acquired cardiovascular defects with hemodynamically significant residual disease.
- ✕ History of underlying or laboratory evidence of underlying intestinal, metabolic, autoimmune, renal disease that can alter rosuvastatin disposition\* (absorption, metabolism, distribution, or clearance)
- ✕ Pharmacotherapy that interacts with statins (OATP1B1 inducers/inhibitors) \*
- ✕ Inability to swallow a tablet
Where it's recruiting
Missouri
Kansas City
Source: ClinicalTrials.gov · NCT04903223 · last updated 2026-06-25